Avadel製藥 AVDL 深 滬
已收盤 02-06 16:00:00 美东时间
21.69
+0.090
+0.42%
華盛通- 最 高21.70
- 今 開21.60
- 成交量 107.70万股
- 最 低 21.59
- 昨 收 21.60
- 總市值 21.29亿
- 52周最高 23.57
- 市盈率 靜 --
- 換手率 1.10%
- 52周最低 6.38
- 委 比 31.87%
- 總股本 9815.15万
- 歷史最高 23.57
- 量 比 0.97
- 振 幅 0.51%
- 歷史最低 1.03
- 每 手 1
- 風險率 5.33%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Avadel Pharmaceuticals Shareholders Approve Proposed Takeover By Alkermes
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a public limited company incorporated in Ireland ("Avadel" or the "Company") announces today that, in relation to the previously announced offer for the Company by Alkermes plc,
01-13 05:08
Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes
Avadel Pharmaceuticals shareholders have approved the proposed transaction with Alkermes plc, including the scheme of arrangement and amendments to the company’s articles of association, at a special meeting held earlier today. Shareholders also approved the proposed compensatory arrangements for the transaction. Avadel is a biopharmaceutical company focused on transforming medicines to improve patient lives, with LUMRYZ™ as its commercial produc...
01-12 21:05
Catalyst Watch: Big bank earnings, major healthcare + retail conferences, Fedspeak flurry, CPI
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - January 1...
01-10 04:00
不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
那些关于药品定价政策及可能侵蚀利润的关税措施的最坏担忧均未成真，行业焦虑情绪得到明显缓解。 智通财经APP获悉，下周，制药商们将赴旧金山出席摩根大通医疗健康年...
01-10 00:49
不再迷惘的制药商：2025年并购额暴涨124%，巨头狂扫创新药资产
下周，制药商们将赴旧金山出席摩根大通医疗健康年会，心态较2025年显著放松。回溯一年前，他们还对美国总统唐纳德·特朗普的政策走向感到困惑迷惘;如今，此前笼罩的诸...
01-09 21:50
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
01-02 01:35
Avadel Pharmaceuticals Announces Completion of Enrollment in Phase 3 REVITALYZ™ Trial in Idiopathic Hypersomnia
Avadel Pharmaceuticals completed patient enrollment in the Phase 3 REVITALYZ trial evaluating LUMRYZ as a potential treatment for idiopathic hypersomnia (IH). The trial aims to assess LUMRYZ's efficacy and safety as a once-at-bedtime treatment for IH, targeting excessive daytime sleepiness and sleep inertia. LUMRYZ, an extended-release sodium oxybate, has shown benefits for narcolepsy patients and holds potential for IH if approved. Data expected...
2025-12-18 12:00
Avadel Pharmaceuticals Acquisition Moves Forward with HSR Expiry
Avadel Pharmaceuticals ( ($AVDL) ) has issued an update. On December 8, 2025, t...
2025-12-10 05:52
Alkermes To Acquire Avadel Pharmaceuticals In Shareholder Scheme, Sends Proposal To Equity And Employee Share Purchase Plan Holders
As previously announced, the board of directors of Avadel Pharmaceuticals plc (NASDAQ:AVDL), a public limited company incorporated in Ireland (the "Company" or "Avadel") and the board of directors of Alkermes plc
2025-12-06 05:03
Announcement relating to convening of Scheme Meeting and Extraordinary General Meeting
Avadel Pharmaceuticals and Alkermes have agreed to terms for Alkermes to acquire Avadel through a scheme of arrangement under Irish law. The Irish High Court has approved the plan, and a shareholder meeting will be held on January 12, 2026, to vote on the transaction. A proxy statement outlining the terms and conditions of the proposed transaction has been mailed to shareholders.
2025-12-01 21:05
